CBDA-Rich Cannabinoid Compositions for Low-THC Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved cannabinoid compositions and treatments for neurological disorders, particularly those that address neuroinflammation and microglial activation, which are associated with conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other CNS pathologies, while avoiding the psychotropic effects of traditional cannabinoids like THC.
Innovation Solution
A composition comprising about 50 w/w % of CBDA and up to 15 w/w % of other cannabinoids, including CBD, CBG, CBDP, CBDB, CBGA, and CBN, with THC limited to less than 1%, formulated to target neuroinflammation and microglial activation without significant psychoactive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cannabinoids like THC are used to treat neurological disorders, then therapeutic effects are achieved, but psychotropic effects and harmful side effects occur
Solution Approach 1:
The patent extracts and isolates CBDA (cannabidiolic acid) as the primary active component, removing THC and other psychotropic cannabinoids from the composition. This extraction approach allows retention of therapeutic anti-inflammatory and neuroprotective effects while eliminating psychotropic side effects, directly resolving the contradiction between therapeutic reliability and harmful psychotropic factors
Solution Approach 2:
The patent changes the chemical composition parameters by specifying precise concentration ranges: CBDA at 40-60% (preferably 50%), CBD at 1-5%, CBG at 1-10%, and THC limited to <1%. This parameter optimization ensures therapeutic efficacy through CBDA while maintaining safety by limiting psychoactive components, thereby resolving the contradiction between therapeutic effect and harmful psychotropic effects
2Reliability
If high concentrations of THC are used to achieve therapeutic effects, then neurological disorder treatment is improved, but safety and tolerability deteriorate
Solution Approach 1:
The patent removes THC from the composition entirely or limits it to trace amounts (<1%), extracting only the non-psychoactive cannabinoid components (CBDA, CBD, CBG). This extraction strategy maintains treatment efficacy through alternative mechanisms while dramatically improving safety and tolerability profiles
Solution Approach 2:
The patent fundamentally changes the THC concentration parameter from high levels (typically 5-20% in conventional cannabis) to trace amounts (<1%), while optimizing other cannabinoid parameters (CBDA 40-60%, CBD 1-5%, CBG 1-10%). This parameter transformation preserves therapeutic effectiveness through CBDA-mediated mechanisms while eliminating THC-related safety concerns
3Reliability
If conventional cannabis compositions are used, then neurological disorder treatment is provided, but neuroinflammation and microglial activation are not sufficiently addressed
Solution Approach 1:
The patent applies local quality by optimizing the composition specifically for neuroinflammatory conditions. The CBDA-rich formulation (40-60%) provides targeted anti-inflammatory action in the central nervous system, while the absence of THC prevents psychoactive interference. This localized optimization ensures the treatment specifically addresses neuroinflammation and microglial activation without compromising overall treatment coverage
Solution Approach 2:
The patent changes the compositional parameters to prioritize CBDA (40-60%) over other cannabinoids, creating a formulation specifically optimized for neuroinflammatory pathologies. This parameter shift enhances target specificity for microglial and astrocyte modulation while maintaining broad treatment coverage for various neurological conditions through the multi-cannabinoid synergistic effect
Data Source
AI summary
The present invention relates to compositions comprising cannabinoids. The present invention also relates to pharmaceutical compositions, dosage forms and methods of treating neurological disorders by administering the composition to a patient in need thereof.